je.st
news
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen
2015-07-06 15:29:07| Biotech - Topix.net
Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. , announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen for the treatment of patients with Familial Chylomicronemia Syndrome . FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis.
Tags: drug
designation
fda
obtains
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||